18:12 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies suggest inhibition or inverse agonism of NR5A2 could help treat prostate cancer. In a human prostate cancer line expressing high levels of NR5A2 cultured in androgen-deprived bovine serum, siRNA targeting...
07:00 , Jun 13, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Nuclear receptor subfamily 5 group A member 2 (NR5A2; LRH-1) ...
07:00 , Oct 6, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Nuclear receptor subfamily 5 group A member 2 (NR5A2; LRH-1) In vitro studies suggest inhibiting...
07:00 , Jun 9, 2011 |  BC Innovations  |  Targets & Mechanisms

Nuclear receptor in the crosshairs of diabetes

Researchers at the Baylor College of Medicine and Scripps Florida have identified a new signaling pathway that could be targeted to treat type 2 diabetes.1 The group has shown that activating the nuclear receptor LRH-1...
07:00 , Jun 9, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Nuclear receptor subfamily 5 group A member 2 (NR5A2; LRH-1)...